Search Results

Business

Fluicell Has In-Licensed the Dynaflow Resolve Secondary Ion Channel Screening Platform Technology From Cellectricon

Fluicell is extremely pleased to announce the signing of a license agreement with Cellectricon, granting the exclusive right, inter alia, to sell the Dynaflow Resolve technology worldwide and to use the related IP rights.

November 3, 2017

·

3 min read

Fluicell Receives A New Patent Acceptance For The BioPen System

July 24, 2017

·

1 min read

FDA

Fluicell Receives Green Light With A New BioPen Patent In The U.S.A.

June 14, 2017

·

1 min read

Science Advances publishes proteomics technology from Oblique Therapeutics AB with a potential to bring several novel antibody medicines to large patient populations in multiple disease areas

Oblique Therapeutics AB, a Sweden-based biotech company, in collaboration with Karolinska Institutet, Gothenburg University and several local biotechs published promising research results in the highly-acclaimed scientific journal Science Advances entitled: Rational Antibody design for Undruggable Targets using Kinetically Controlled Biomolecular probes.

April 19, 2021

·

6 min read